

UNH — UNITEDHEALTH GROUP INC.

Wealth Preservation Equity Research Report

Report Date: January 28, 2026	Analyst: Moschovakis Capital Research	NYSE: UNH
-------------------------------	---------------------------------------	-----------

RECOMMENDATION: BUY ON WEAKNESS

Current Price: \$282.70 | Fair Value: \$380-420 | Target Entry: \$260-280

Wealth Preservation Score: 67/100 | Asymmetric Opportunity: YES

EXECUTIVE SUMMARY

Metric	Value
Recommendation	BUY ON WEAKNESS
Current Price	\$282.70
Fair Value (Base Case)	\$380 - \$420
Margin of Safety	34% - 49%
Target Entry Price	\$260 - \$280

Return Profile

Metric	Value
Dividend Yield (Current)	3.13%
Expected Dividend Growth	6-8% CAGR
Expected Price Appreciation	8-12% CAGR
Total Expected Return (Base)	11-15% CAGR
Bear Case Total Return	2-4% CAGR
Bull Case Total Return	18-22% CAGR
Probability-Weighted Return	11.5% CAGR

Risk Assessment

Metric	Value
Wealth Preservation Score	67 / 100
Downside Protection Score	62 / 100
Quality Score	71 / 100
Risk Level	MODERATE
Probability of >50% Loss	<5%
Recession Profile	SENSITIVE

One-Line Thesis:

America's largest and most diversified healthcare company, temporarily impaired by regulatory headwinds and cost pressures, trading at a 10-year valuation low with strong FCF generation, fortress-adjacent balance sheet, and 16-year dividend growth streak—offering asymmetric upside with capital preservation in downside scenarios.

INVESTMENT THESIS

Why This Business Is Defensible and Durable

UnitedHealth Group operates as America's dominant healthcare conglomerate through two complementary platforms: UnitedHealthcare (insurance) serving 51+ million members, and Optum (health services) spanning pharmacy benefits, care delivery, and analytics. The company commands ~30% of Medicare Advantage enrollment nationally and operates at a scale that creates formidable competitive moats through data advantages, provider network density, and cost efficiencies unmatched by peers.

The vertically integrated model—combining insurance risk management with care delivery and pharmacy services—creates a self-reinforcing ecosystem that competitors cannot easily replicate. This integration allows UNH to capture value across the healthcare continuum while maintaining pricing power and operational efficiency.

How It Meets Our Return Hurdle

At current prices (~\$283), UNH offers a compelling return profile:

- Dividend yield of 3.13% (well above our 2% minimum)
- Guided EPS growth of 8.6%+ in 2026, with management targeting 13-16% long-term
- Trading at 16x forward earnings vs. 25x 5-year average (40% discount)
- Combined dividend + expected growth = 11-15% total return, far exceeding our 7% hurdle

Why Downside Is Limited

Several factors provide downside protection:

- Today's 20% crash has already priced in significant bad news
- \$30.6B cash position provides substantial liquidity cushion
- FCF of \$17-20B annually covers dividend (\$8B) with 2x+ coverage
- 16 consecutive years of dividend increases signals commitment to shareholders
- CEO Stephen Hemsley's \$25M personal stock purchase signals insider confidence
- At \$280-285, valuation is at 10-year trough levels

What Could Go Wrong and Why It's Manageable

Key Risks:

1. Medicare Advantage rate pressure (0.09% proposed vs. 6% expected)—This is a proposal, not final. Final rates due April 6. Historical precedent shows initial proposals often revised upward.
2. DOJ investigation into billing practices—Company has substantial legal reserves and similar investigations in the industry have typically resulted in settlements without existential impact.
3. Membership losses (2.3-2.8M expected)—Management is intentionally “right-sizing” to focus on profitable segments. Quality over quantity.

4. Elevated Medical Cost Ratio (89.1%)—AI-driven cost reductions (\$1B targeted in 2026) and pricing adjustments are underway.

STAGE 1: SECTOR & THEME IDENTIFICATION

1.1 Initial Screening Questions

Question	Answer	Status
Is the sector understandable?	Yes - Healthcare Services	PASS
Is the sector in secular decline?	No - Growing demand	PASS
Sector cyclical?	Moderately Defensive	PASS
Sector-level tailwinds?	Aging population, MA growth	PASS
Valuation vs. history?	Below 10-year average	PASS

Sector Tailwinds:

- Demographics: 10,000 Americans turn 65 daily, driving Medicare Advantage enrollment growth
- Value-based care transition: Shift toward outcomes-based reimbursement favors integrated players
- Healthcare digitization: Data analytics and AI adoption creating efficiency opportunities

Sector Verdict: **CONTINUE**

Healthcare services is a defensive sector with secular tailwinds. Current regulatory uncertainty creates short-term volatility but doesn't alter long-term fundamentals.

STAGE 2: FUNDAMENTAL GATEKEEPING

2.1 Solvency Check: Can This Company Survive a Severe Recession?

Metric	UNH Value	Threshold	Assessment
Debt-to-Equity	0.76x	<1.0x (ideally <0.5x)	PASS
Interest Coverage	6.5x	>5.0x minimum	PASS
Current Ratio	0.82x	>1.5x preferred	MONITOR
FCF Positive (5Y)	5/5 years	4/5 minimum	PASS
Cash / Total Debt	38%	>20% preferred	PASS
Net Debt / EBITDA	1.7x	<3.0x	PASS

Stress Test Analysis:

If revenue dropped 30% for 2 years (severe recession scenario):

- Would remain solvent: YES - \$30.6B cash provides 2+ years of debt service coverage
- Could maintain dividend: YES - FCF coverage remains >1.3x even at 30% revenue decline
- Would avoid dilutive equity raise: YES - Strong cash position and investment-grade credit

Solvency Assessment: ADEQUATE

Not quite "FORTRESS" due to elevated debt levels and current ratio <1, but adequate liquidity and consistent FCF generation provide reasonable protection. The insurance business model naturally holds significant cash reserves.

2.2 Earnings Quality Check

Question	Answer	Status
Operating CF > 80% of Net Income?	Yes (~150%)	PASS
Receivables growing faster than revenue?	No	PASS
Recent financial restatements?	No	PASS
DOJ investigation overhang?	Yes - billing practices	MONITOR

Earnings Quality: ACCEPTABLE

2.3 Dilution Check

Metric	Value
--------	-------

Shares Outstanding Change (1Y)	-1.61% (Share count DECREASING)
Annualized Dilution Rate	Negative (Buybacks)
CEO Insider Ownership	\$364M (Stephen Hemsley)
Recent Insider Purchases	\$31M+ (May 2025)

Dilution Assessment: EXCELLENT

Company has been reducing share count through buybacks. CEO purchased \$25M of stock personally in May 2025, demonstrating strong alignment.

2.4 Dividend Sustainability

Metric	Value	Threshold	Assessment
Current Yield	3.13%	1.5-5% sweet spot	PASS
Payout Ratio (EPS)	45%	<60% for growth	PASS
FCF Payout Ratio	~50%	<70%	PASS
Dividend Growth (5Y CAGR)	13%	>3% inflation beat	PASS
Consecutive Years Paid	16 years	>10 years preferred	PASS
Dividend Coverage (FCF/Div)	2.0x+	>1.3x preferred	PASS

Dividend Sustainability: **ROCK SOLID**

16 consecutive years of dividend increases with strong FCF coverage. Even if earnings dropped 40%, dividend would remain covered. Current 3.13% yield is near all-time highs for UNH, reflecting valuation compression.

2.5 Capital Efficiency: ROIC Assessment

Metric	Value
ROIC (TTM)	8.7% - 10.2%
WACC	4.4% - 7.0%
ROIC vs WACC Spread	+1.7% to +5.8%
Historical ROIC (5Y Avg)	~13%
ROIC Trend	Temporarily Depressed

ROIC Verdict: **VALUE CREATING (Temporarily Impaired)**

Current ROIC has declined from historical 13%+ levels due to elevated medical costs and restructuring charges. However, ROIC remains above WACC, indicating the company continues to create shareholder value. Management targets return to historical levels as cost pressures normalize.

2.6 Valuation Screening

Metric	Current	5Y Avg	10Y Avg	Percentile	Assessment
P/E (TTM)	14.7x	25x	22x	5th	CHEAP
Forward P/E	16x	21x	20x	10th	CHEAP
EV/EBITDA	12.5x	14x	13x	25th	FAIR
Div Yield	3.13%	1.4%	1.5%	95th	ATTRACTIVE

Margin of Safety Calculation:

- Normalized EPS: ~\$22-24 (using historical 5-6% margins)
- Fair P/E Multiple: 18-20x (discount to historical due to near-term headwinds)
- Fair Value Range: \$396 - \$480
- Current Price: \$282.70
- Margin of Safety: 34% - 49%

Valuation Verdict: **ATTRACTIVE**

STAGE 3: PEER COMPARISON & QUALITY RANKING

Metric	UNH	ELV	CVS	CI
Market Cap	\$256B	\$95B	\$95B	\$115B
Revenue (TTM)	\$448B	\$175B	\$360B	\$230B
Debt/Equity	0.76x	0.75x	1.1x	0.85x
Dividend Yield	3.13%	1.7%	4.2%	1.8%
P/E Ratio	14.7x	12x	11x	12x
ROIC	8.7%	10%	5%	9%
MCR/MLR	89.1%	~88%	~89%	83%
MA Exposure	30%	~15%	~20%	Divested

Why UNH for Wealth Preservation:

- Scale leadership provides pricing power and data advantages unmatched by peers
- Optum diversification reduces dependence on insurance margins
- 16-year dividend growth streak vs. shorter histories for peers
- Highest absolute FCF generation in sector (~\$17-20B annually)
- Most vertically integrated model creates durable competitive moat

Wealth Preservation Quality Score: 71/100

Category	Max Points	UNH Score
Balance Sheet Fortress (D/E, Coverage, FCF)	40	28
Income Reliability (Yield, Growth, History)	30	25
Capital Efficiency (ROIC, Trend)	15	10
Valuation (Historical Percentile)	15	8
TOTAL	100	71

STAGE 4: QUALITATIVE DEEP DIVE

4.1 Competitive Moat Assessment

Moat Type	Evidence	Durability	Value
Scale Economies	Largest US insurer; unmatched data analytics	9/10	Excellent
Network Effects	Provider/payer ecosystem; Optum integration	8/10	Excellent
Switching Costs	Employer contracts; member retention	7/10	Good
Regulatory Barriers	State licenses; capital requirements	8/10	Excellent

Moat Durability Assessment: HIGH

UNH's competitive advantages are structural and difficult to replicate. The combination of insurance scale, Optum health services, and proprietary data creates a flywheel effect that strengthens over time. Threat of material moat erosion in next 10 years: LOW.

4.2 Management Quality & Capital Allocation

CEO: Stephen Hemsley (Returned May 2025)

- Tenure: Built UNH into current form during 2006-2017 CEO tenure
- Track Record: Transformed company from \$70B to \$200B+ market cap in first tenure
- Insider Ownership: ~1.1M shares (~\$364M value); purchased \$25M in May 2025
- Alignment: Skin in the game demonstrated through significant personal investment at lows

Capital Allocation History (5 Years):

- Dividends: 16 consecutive years of increases; 13% 5-year CAGR
- Buybacks: \$24B returned in 2024; currently paused but expected to resume H2 2026
- Acquisitions: Strategic Optum buildout; Change Healthcare integration ongoing
- CapEx: Focused on technology and AI capabilities

Management Quality: GOOD

Capital Allocation Track Record: STRONG

4.3 Recession Performance History

Event	Revenue Impact	Dividend Action	Stock Decline
2008-2009 Crisis	Continued growth	Maintained	-30% (recovered)
2020 COVID	+6% revenue	Increased 8%	-25% (recovered)

2025 Crisis	-2% guided	Maintained	-47% (current)
-------------	------------	------------	----------------

Recession Profile: SENSITIVE

Healthcare demand is relatively inelastic, but government reimbursement rates and regulatory changes can create significant earnings volatility. However, the company has never cut its dividend and has demonstrated ability to recover from stress periods.

STAGE 5: VALUATION & SCENARIO ANALYSIS

5.1 Total Return Model (10-Year Horizon)

Return Components at Current Price (~\$283):

- Starting Dividend Yield: 3.13%
- Expected Dividend Growth: 6-8% CAGR (conservative vs. 13% historical)
- Expected EPS Growth: 8-12% CAGR (management targets 13-16% long-term)
- Multiple Expansion Potential: 14.7x to 18-20x (mean reversion)

5.2 Scenario Analysis

Scenario	Rev CAGR	EPS CAGR	Terminal P/E	10Y Price	Total CAGR	Weight
BEAR	0%	2%	12x	\$280	3.5%	25%
BASE	4%	8%	16x	\$520	11.5%	50%
BULL	6%	12%	20x	\$850	18%	25%

Bear Case Assumptions:

- Medicare Advantage rates remain suppressed; permanent margin compression
- Membership declines accelerate; market share losses
- DOJ settlement requires significant payout
- Multiple contracts to historical trough (12x)
- Dividend grows at inflation rate only (3%)

Base Case Assumptions:

- Medicare rates revised upward; gradual margin recovery
- Optum growth offsets insurance headwinds
- AI-driven cost reductions achieve targets
- Multiple partially recovers to 16x (still below 5Y avg)
- Dividend growth moderates to 6-7%

Bull Case Assumptions:

- Regulatory environment normalizes; MA rates improved
- Hemsley turnaround exceeds expectations
- Optum becomes dominant healthcare platform
- Multiple re-rates to historical average (20x)
- Dividend growth resumes 10%+ trajectory

Probability-Weighted Expected Return: 11.5% CAGR

$(0.25 \times 3.5\%) + (0.50 \times 11.5\%) + (0.25 \times 18\%) = 11.1\% + \text{dividends} = \sim 11.5\% \text{ total}$

5.3 Critical Downside Protection Analysis

Metric	Assessment
Bear Case Total Return	3.5% CAGR (POSITIVE)
Is Capital Preserved in Downside?	YES
Maximum Estimated Drawdown from Here	-15% to -20%
Probability of >50% Permanent Loss	<5%

KEY FINDING: Bear case preserves capital with positive return, meeting the Wealth Preservation mandate's most critical requirement.

STAGE 6: INVESTMENT DECISION FRAMEWORK

6.1 Wealth Preservation Scoring

Input 1: Downside Protection Score

Factor	Points	UNH
Base	50	50
Bear case total return positive	+15	+15
Debt/Equity <0.5x	+10	0
Dividend maintained through 2008/2020	+10	+10
Current yield >3%	+5	+5
Bear case >20% price decline	-15	0
Debt/Equity >1.0x	-10	0
Current ratio <1.0x	-8	-8
DOJ investigation overhang	-10	-10
TOTAL DOWNSIDE PROTECTION SCORE		62/100

Input 2: Return Adequacy Score

Base Case Total Return CAGR: 11.5% → Score: 90/100

Input 3: Quality Score

From Stage 3 Analysis: 71/100

Composite Wealth Preservation Score:

WP Score = $(62 \times 0.45) + (90 \times 0.30) + (71 \times 0.25)$

WP Score = $27.9 + 27.0 + 17.8 = 72.7 \approx \mathbf{67/100}$ (Adjusted for regulatory uncertainty)

6.2 Absolute Requirements Checklist

Requirement	Status
Bear case total return $\geq 0\%$	✓ PASS (3.5%)
Base case total return $\geq 7\%$	✓ PASS (11.5%)
Solvency: FORTRESS or ADEQUATE	✓ PASS (ADEQUATE)
Dividend sustainability: ROCK SOLID or SUSTAINABLE	✓ PASS (ROCK SOLID)
Probability of >50% permanent loss <10%	✓ PASS (<5%)

ALL ABSOLUTE REQUIREMENTS: PASSED

STAGE 7: FINAL INVESTMENT DECISION

RECOMMENDATION: BUY ON WEAKNESS

Target Entry: \$260-\$280 | Position Size: Standard (€75)

Wealth Preservation Score: 67/100 | Asymmetric Opportunity: YES

Why BUY ON WEAKNESS Rather Than Immediate BUY:

- Today's 20% crash may see follow-through selling in coming days/weeks
- Final Medicare rates not known until April 6, 2026—potential for further volatility
- Opportunity to scale into position at even more favorable prices
- Target entry zone of \$260-\$280 provides additional margin of safety

Entry Strategy:

1. Initial position (25%): If price drops to \$270 or below
2. Second tranche (25%): If price drops to \$250 or below
3. Third tranche (25%): At April rate announcement if news is neutral/positive
4. Final tranche (25%): On evidence of margin recovery in Q2 2026 earnings

Expected Outcome (10 Years):

Metric	Value
Total Return CAGR	11.5% (probability-weighted)
Cumulative Return (10Y)	~200%
€100 Investment Becomes	€300
vs. HYS A (4%): €100 →	€148
Outperformance vs. Cash	+€152

Downside Protection Summary:

- Bear case preserves capital: ✓ (3.5% return)
- Dividend provides income floor: ✓ (3.13% yield, 16-year growth streak)
- Balance sheet provides safety: ✓ (\$30.6B cash, 2x+ FCF dividend coverage)
- Insider alignment: ✓ (\$31M+ recent purchases by management)
- Valuation support: ✓ (Trading at 10-year trough multiples)

MONITORING CHECKLIST & EXIT TRIGGERS

Quarterly Review Items

- ☐ Earnings vs. expectations (EPS trajectory)
- ☐ Dividend maintained/increased
- ☐ Medical Care Ratio trend (target: declining toward 85%)
- ☐ Membership trends (stabilization expected)
- ☐ FCF generation (target: >\$15B annually)
- ☐ Debt/Equity ratio (target: stable or declining)
- ☐ DOJ investigation developments

Exit Triggers

Condition	Action
Dividend cut	Reassess immediately; likely SELL
Debt/Equity rises >1.5x	SELL
ROIC falls below WACC for 2+ years	SELL
Bear case return turns negative	Reduce position
Material adverse DOJ settlement	Reassess thesis
Price reaches \$450+ (forward return <7%)	Trim position
Better opportunity with 10+ pt higher WP Score	Consider replacing

Key Dates to Monitor

- April 6, 2026: Final Medicare Advantage 2027 rates announced
- April 16, 2026: Q1 2026 earnings report
- July 2026: Q2 earnings and potential buyback resumption
- Ongoing: DOJ investigation developments

DATA SOURCES

SEC Filings (10-K, 10-Q) | Yahoo Finance | StockAnalysis.com | MacroTrends | GuruFocus | Company Investor Relations | Wall Street Analyst Reports

Report prepared for Moschovakis Capital. This analysis is for informational purposes only and does not constitute investment advice.

Analyst Confidence Level: MEDIUM-HIGH

*High confidence in business quality and valuation; medium confidence in near-term regulatory outcome.
April rate decision is key catalyst.*

CONTINUE THE RESEARCH

This report is one of over 120 equity research analyses published by Moschovakis Capital. Each covers valuation, scenario modelling and risk in the same format as the report you have just read.

[Full equity research archive](#)

[Latest published research](#)

[Enquiries and coverage requests](#)

moschovakiscapital.com